US20110014230A1 - preparation of influenza virus vaccine antigens - Google Patents
preparation of influenza virus vaccine antigens Download PDFInfo
- Publication number
- US20110014230A1 US20110014230A1 US12/933,379 US93337909A US2011014230A1 US 20110014230 A1 US20110014230 A1 US 20110014230A1 US 93337909 A US93337909 A US 93337909A US 2011014230 A1 US2011014230 A1 US 2011014230A1
- Authority
- US
- United States
- Prior art keywords
- influenza
- virions
- detergent
- virus
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [H]C12C(O)C(*O)CN1C(CO)C(O)C2O Chemical compound [H]C12C(O)C(*O)CN1C(CO)C(O)C2O 0.000 description 2
- MCJGIOYECQAXBX-PVKVKGENSA-N CC#CC#CC#C[C@H](CCOC[C@H](COP(=O)(O)OCCNC(=O)NCCOP(=O)(O)OC[C@@H](COCC[C@@H](C#CC#CC#CC)OC(=O)CCCCCCCCCCC)NC(=O)CC(=O)CCCCCCCCCCC)NC(=O)CC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCC.CCCCCCCCCCCCCC(=O)N[C@@H](COCC[C@@H](CCCCCCC)OC(=O)CCCCCCCCCCC)COP(=O)(O)OCCNC(=O)NCCOP(=O)(O)OC[C@@H](COCC[C@@H](CCCCCCC)OC(=O)CCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[NaH].[NaH] Chemical compound CC#CC#CC#C[C@H](CCOC[C@H](COP(=O)(O)OCCNC(=O)NCCOP(=O)(O)OC[C@@H](COCC[C@@H](C#CC#CC#CC)OC(=O)CCCCCCCCCCC)NC(=O)CC(=O)CCCCCCCCCCC)NC(=O)CC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCC.CCCCCCCCCCCCCC(=O)N[C@@H](COCC[C@@H](CCCCCCC)OC(=O)CCCCCCCCCCC)COP(=O)(O)OCCNC(=O)NCCOP(=O)(O)OC[C@@H](COCC[C@@H](CCCCCCC)OC(=O)CCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[NaH].[NaH] MCJGIOYECQAXBX-PVKVKGENSA-N 0.000 description 1
- UPNYPTVRZHMEOB-XQBWSMNBSA-N CCCCCC/C=C\CCCCCCCCCC(=O)N[C@@H]1/C(=O/CC[C@H](CO)CCCCCCC)[C@H](O)[C@@H](CCO)O[C@H]1OCC1O[C@H](OP(=O)(O)O)[C@H](NC(=O)CC(=O)CCCCCCCCCCC)/C(=O\CCCCCCCCCC)[C@@H]1O.O=POO Chemical compound CCCCCC/C=C\CCCCCCCCCC(=O)N[C@@H]1/C(=O/CC[C@H](CO)CCCCCCC)[C@H](O)[C@@H](CCO)O[C@H]1OCC1O[C@H](OP(=O)(O)O)[C@H](NC(=O)CC(=O)CCCCCCCCCCC)/C(=O\CCCCCCCCCC)[C@@H]1O.O=POO UPNYPTVRZHMEOB-XQBWSMNBSA-N 0.000 description 1
- TZYVRXZQAWPIAB-FCLHUMLKSA-N [H][C@@]1(N2C(=O)SC3=C2NC(N)=NC3=O)O[C@H](CO)[C@@H](O)[C@H]1O Chemical compound [H][C@@]1(N2C(=O)SC3=C2NC(N)=NC3=O)O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
Definitions
- influenza virions are maintained before, during and after splitting in a Tris buffer.
- the virions are maintained before, during and after splitting in a phosphate buffer. This buffer change has been associated with a >20-fold increase in antigen yield, in particular with a H5 subtype influenza A virus.
- the virus harvest prior to the capture step is subjected to an ultra-/diafiltration step into a low conductivity buffer.
- This initial step can result in up to a 10-fold increase of antigen yield depending on the influenza virus strain, and is particularly useful for virions that do not bind to the capture agent.
- the invention protects against a strain that is capable of human-to-human transmission, and so the strain's genome will usually include at least one RNA segment that originated in a mammalian (e.g. in a human) influenza virus. It may include NS segment that originated in an avian influenza virus.
- Treatment with ⁇ -propiolactone is particularly useful, as disclosed in reference 68.
- the ⁇ -propiolactone may be present in a phosphate buffer.
- a process of the invention for disrupting influenza virions can be used as part of an overall process for preparing a split virus vaccine or for preparing a purified surface antigen vaccine.
- a hemagglutinin-containing antigen preparation will be obtained from a virus by a process in which influenza virions are disrupted by a process as described herein.
- the hemagglutinin-containing antigen preparation will then be used to prepare the vaccine, also as described herein.
- Preferred adjuvants for use with the invention are oil-in-water emulsions, which have been found to be particularly suitable for use in adjuvanting influenza virus vaccines.
- Various such emulsions are known, and they typically include at least one oil and at least one surfactant, with the oil(s) and surfactant(s) being biodegradable (metabolisable) and biocompatible.
- the oil droplets in the emulsion are generally less than 5 ⁇ m in diameter, and ideally have a sub-micron diameter, with these small sizes being achieved with a microfluidiser to provide stable emulsions. Droplets with a size less than 220 nm are preferred as they can be subjected to filter sterilization.
- composition includes a tocopherol
- any of the ⁇ , ⁇ , ⁇ , ⁇ , ⁇ or ⁇ tocopherols can be used, but ⁇ -tocopherols are preferred.
- the tocopherol can take several forms e.g. different salts and/or isomers. Salts include organic salts, such as succinate, acetate, nicotinate, etc. D- ⁇ -tocopherol and DL- ⁇ -tocopherol can both be used.
- Tocopherols are advantageously included in vaccines for use in elderly patients (e.g. aged 60 years or older) because vitamin E has been reported to have a positive effect on the immune response in this patient group [169].
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/933,379 US20110014230A1 (en) | 2008-03-18 | 2009-03-18 | preparation of influenza virus vaccine antigens |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6986808P | 2008-03-18 | 2008-03-18 | |
US12/933,379 US20110014230A1 (en) | 2008-03-18 | 2009-03-18 | preparation of influenza virus vaccine antigens |
PCT/IB2009/005122 WO2009115917A2 (en) | 2008-03-18 | 2009-03-18 | Improvements in preparation of influenza virus vaccine antigens |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2009/005122 A-371-Of-International WO2009115917A2 (en) | 2008-03-18 | 2009-03-18 | Improvements in preparation of influenza virus vaccine antigens |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/961,778 Continuation US10946088B2 (en) | 2008-03-18 | 2015-12-07 | Preparation of influenza virus vaccine antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110014230A1 true US20110014230A1 (en) | 2011-01-20 |
Family
ID=41091288
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/933,379 Abandoned US20110014230A1 (en) | 2008-03-18 | 2009-03-18 | preparation of influenza virus vaccine antigens |
US14/961,778 Active US10946088B2 (en) | 2008-03-18 | 2015-12-07 | Preparation of influenza virus vaccine antigens |
US17/151,840 Pending US20210205438A1 (en) | 2008-03-18 | 2021-01-19 | Preparation of influenza virus vaccine antigens |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/961,778 Active US10946088B2 (en) | 2008-03-18 | 2015-12-07 | Preparation of influenza virus vaccine antigens |
US17/151,840 Pending US20210205438A1 (en) | 2008-03-18 | 2021-01-19 | Preparation of influenza virus vaccine antigens |
Country Status (11)
Country | Link |
---|---|
US (3) | US20110014230A1 (ja) |
EP (3) | EP3459563A1 (ja) |
JP (1) | JP5518041B2 (ja) |
KR (1) | KR20100135766A (ja) |
CN (1) | CN101998990B (ja) |
AU (1) | AU2009227674C1 (ja) |
CA (1) | CA2718430A1 (ja) |
EA (1) | EA201071086A1 (ja) |
ES (1) | ES2535101T3 (ja) |
NZ (1) | NZ587798A (ja) |
WO (1) | WO2009115917A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110200635A1 (en) * | 2008-06-12 | 2011-08-18 | Novartis Ag | Combined influenza vaccines for seasonal and pandemic protection |
US9821051B1 (en) * | 2010-10-28 | 2017-11-21 | Seqirus UK Limited | Reducing hospitalization in elderly influenza vaccine recipients |
US10144917B2 (en) | 2014-08-29 | 2018-12-04 | Calixar | Method for preparing a vaccine antigen, resulting vaccine antigen and uses |
RU2741003C1 (ru) * | 2020-03-27 | 2021-01-22 | Евгений Дмитриевич Некрасов | Способ производства четырехвалентной субъединичной вакцины против гриппа без адъювантов |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11707520B2 (en) * | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
GB0918830D0 (en) | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
SG184804A1 (en) | 2010-04-30 | 2012-11-29 | Temasek Life Sciences Lab Ltd | Universal vaccine against h5n1 lineages |
ES2653197T3 (es) * | 2011-07-20 | 2018-02-06 | Bgp Products B.V. | Procedimiento para producir antígeno ortomixoviral y vacunas |
JP6136236B2 (ja) * | 2012-12-19 | 2017-05-31 | 東ソー株式会社 | 組換えタンパク質の精製方法 |
RU2710239C1 (ru) * | 2019-06-14 | 2019-12-25 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства | Способ получения антигена или антигенов для производства противогриппозной вакцины и вакцина на его основе |
JP2023500873A (ja) * | 2019-11-07 | 2023-01-11 | セキラス ユーケー リミテッド | 低減した粒度を有するウイルスワクチンを生成するための組成物および方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001022992A2 (en) * | 1999-09-30 | 2001-04-05 | Smithkline Beecham Biologicals S.A. | Influenza vaccine |
WO2006100110A1 (en) * | 2005-03-23 | 2006-09-28 | Glaxosmithkline Biologicals S.A. | Novel composition |
WO2007052057A2 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Adminstration routes for priming/boosting with influenza vaccines |
US20080014217A1 (en) * | 2006-07-17 | 2008-01-17 | Emmanuel Jules Hanon | Influenza vaccine |
US20090285854A1 (en) * | 2006-07-20 | 2009-11-19 | Novartis Ag | Frozen stockpiling of influenza vaccines |
Family Cites Families (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3316153A (en) * | 1965-03-29 | 1967-04-25 | Lilly Co Eli | Virus purification |
AU405949B1 (en) | 1966-02-24 | 1970-09-18 | The Australian National University | Influenza virus sub-unit vaccine |
US3962421A (en) * | 1973-06-18 | 1976-06-08 | American Home Products Corporation | Method for the disruption of lipid-containing viruses |
US4158054A (en) | 1973-10-18 | 1979-06-12 | Duncan Flockhart & Co. Ltd. | Preparation of virus sub-unit vaccines |
US4140762A (en) | 1974-01-14 | 1979-02-20 | Sandoz Ltd. | Influenza sub-unit vaccine |
US4064232A (en) | 1974-01-14 | 1977-12-20 | Sandoz Ltd. | Process for isolating the immunogenic components of influenza viruses |
US4060082A (en) | 1976-08-16 | 1977-11-29 | Mpl, Inc. | Dual-ingredient medication dispenser |
DE2816086C3 (de) | 1978-04-13 | 1985-04-25 | Sartorius GmbH, 3400 Göttingen | Asymmetrische Ultrafiltrationsmembrane auf der Basis von Zellulosetriacetat |
US4327182A (en) | 1981-01-22 | 1982-04-27 | Connaught Laboratories Incorporated | Purification of influenza sub-unit vaccine |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
AU627226B2 (en) | 1988-08-25 | 1992-08-20 | Liposome Company, Inc., The | Influenza vaccine and novel adjuvants |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
DK0582581T3 (da) | 1991-03-01 | 1999-11-08 | Minnesota Mining & Mfg | 1,2-substituerede 1H-imidazo[4,5-c]quinolin-4-aminer |
JPH0614756Y2 (ja) | 1991-06-26 | 1994-04-20 | 株式会社アルテ | 組み立て式の2室式容器兼用注射器 |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
EP0570826A1 (de) | 1992-05-20 | 1993-11-24 | Akzo Nobel N.V. | Celluloseacetatmembranen |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
AU6141094A (en) * | 1993-02-19 | 1994-09-14 | Smithkline Beecham Biologicals (Sa) | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
JPH09500128A (ja) | 1993-07-15 | 1997-01-07 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | イミダゾ〔4,5−c〕ピリジン−4−アミン |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US5522991A (en) | 1994-07-20 | 1996-06-04 | Millipore Investment Holdings Limited | Cellulosic ultrafiltration membrane |
FR2723740B1 (fr) | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
US5496284A (en) | 1994-09-27 | 1996-03-05 | Waldenburg; Ottfried | Dual-chamber syringe & method |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
AU3186297A (en) | 1996-07-05 | 1998-02-02 | Debiotech S.A. | Dual-chamber syringe for mixing two substances prior to injection |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
AU9785598A (en) | 1997-10-03 | 1999-04-27 | Texas Pharmaceuticals, Inc. | Improved dual chamber syringe apparatus |
US5971953A (en) | 1998-01-09 | 1999-10-26 | Bachynsky; Nicholas | Dual chamber syringe apparatus |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
CN1306438A (zh) | 1998-05-07 | 2001-08-01 | 科里克萨有限公司 | 佐剂组合物及其使用方法 |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
DE19835749C1 (de) | 1998-08-07 | 2000-02-03 | Dieter Perthes | Fertig-Spritze für nicht-stabile Arzneimittel |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
EP1126876B1 (en) | 1998-10-16 | 2007-03-21 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
US7169395B1 (en) * | 1998-12-17 | 2007-01-30 | Sanofi Pasteur Limited | Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
DK1150918T3 (da) | 1999-02-03 | 2004-12-20 | Biosante Pharmaceuticals Inc | Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler |
BRPI0009580B8 (pt) | 1999-04-06 | 2021-05-25 | Wisconsin Alumni Res Found | processo para preparar vírus influenza infecciosos na ausência de um vírus auxiliar, preparação de vírus influenza infeccioso recombinante, e, composição. |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
AU5998400A (en) | 1999-07-14 | 2001-01-30 | Mount Sinai School Of Medicine Of The City University Of New York, The | In vitro reconstitution of segmented negative-strand rna viruses |
DE60036952T2 (de) * | 1999-09-24 | 2008-08-07 | Glaxosmithkline Biologicals S.A. | Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung |
AP1775A (en) | 1999-09-25 | 2007-08-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
EP1103610A1 (en) * | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
CA2400468C (en) * | 2000-02-15 | 2012-12-18 | Intellivax International Inc. | Proteosome influenza vaccine |
DE60142506D1 (de) | 2000-03-03 | 2010-08-19 | Chemo Sero Therapeut Res Inst | In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle |
CA2406100C (en) | 2000-04-28 | 2010-11-02 | St. Jude Children's Research Hospital | Dna transfection system for the generation of infectious influenza virus |
FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
DE60140456D1 (de) | 2000-09-01 | 2009-12-24 | Novartis Vaccines & Diagnostic | Aza heterocyclische derivate und ihre therapeutische verwendung |
EA006711B1 (ru) | 2000-09-11 | 2006-02-24 | Чирон Корпорейшн | Хинолиноновые производные в качестве ингибиторов тирозинкиназы |
EP1322656B1 (en) | 2000-09-26 | 2008-01-16 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
EP2269639B1 (en) | 2001-02-23 | 2018-11-28 | GlaxoSmithKline Biologicals s.a. | Influenza vaccine formulations for intradermal delivery |
CA2438960A1 (en) | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
MY134424A (en) * | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
US7321033B2 (en) | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
EA008380B1 (ru) | 2001-11-27 | 2007-04-27 | Анадис Фармасьютикалз, Инк. | 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
CA2480638C (en) | 2002-03-29 | 2013-02-12 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
US6743920B2 (en) | 2002-05-29 | 2004-06-01 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
AU2003268184A1 (en) | 2002-08-23 | 2004-03-11 | Chiron Corporation | Pyrrole based inhibitors of glycogen synthase kinase 3 |
EP1587473A4 (en) | 2002-12-27 | 2008-08-13 | Novartis Vaccines & Diagnostic | THIOSEMICARBAZONES ANTIVIRAL AND IMMUNOSTIMULANTS |
ES2391770T3 (es) | 2003-01-21 | 2012-11-29 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos de triptantrina para la potenciación inmune |
GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
RU2236257C1 (ru) | 2003-09-15 | 2004-09-20 | Косяков Константин Сергеевич | Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами |
US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
WO2005089837A1 (ja) | 2004-03-23 | 2005-09-29 | Nipro Corporation | プレフィルドシリンジ |
EP1732384A4 (en) | 2004-03-31 | 2008-04-23 | Univ New York State Res Found | NOVEL SYNTHETIC C-GLYCOLIPIDES, THEIR SYNTHESIS AND USE FOR THE TREATMENT OF INFECTIONS, CANCER AND AUTOIMMUNE DISEASES |
NZ550152A (en) | 2004-04-05 | 2009-04-30 | Pfizer Prod Inc | Microfluidized oil-in-water emulsions and vaccine compositions |
WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
JP2007537760A (ja) | 2004-05-20 | 2007-12-27 | アイディー バイオメディカル コーポレイション | インフルエンザワクチンを製造するためのプロセス |
DE602005024827D1 (de) | 2004-09-09 | 2010-12-30 | Novartis Vaccines & Diagnostic | Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen |
KR101323459B1 (ko) | 2004-12-23 | 2013-10-29 | 메디뮨 엘엘씨 | 바이러스의 증식을 위한 비종양형성성 mdck 세포주 |
AU2005318087B2 (en) | 2004-12-24 | 2011-04-21 | Abbott Biologicals B.V. | Rescue of influenza virus |
FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
EP1930025B1 (en) | 2005-08-05 | 2013-05-01 | The University of Tokushima | ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE |
JP5602366B2 (ja) | 2005-11-01 | 2014-10-08 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | β−プロピオラクトン処理による低レベルの残存細胞DNAを含む細胞由来のウイルスワクチン |
JP2009514839A (ja) * | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | サイトカイン誘導剤を含むアジュバントインフルエンザワクチン |
CA2628158C (en) * | 2005-11-04 | 2015-12-15 | Novartis Vaccines And Diagnostics S.R.L. | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
CA2628397C (en) * | 2005-11-04 | 2013-08-20 | Novartis Vaccines And Diagnostics S.R.L. | Changing th1/th2 balance in split influenza vaccines with adjuvants |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
EP3753574A1 (en) | 2006-01-27 | 2020-12-23 | Seqirus UK Limited | Influenza vaccines containing hemagglutinin and matrix proteins |
MX2008013388A (es) | 2006-04-19 | 2009-03-02 | Medimmune Llc | Metodos y composiciones para expresar arn viral en sentido negativo en celulas caninas. |
KR20090016704A (ko) * | 2006-06-15 | 2009-02-17 | 노파르티스 아게 | 보조제-보존 수회-투여 인플루엔자 접종 요법 |
MX2009000660A (es) | 2006-07-17 | 2009-04-08 | Glaxosmithkline Biolog Sa | Vacuna de influenza. |
CN1911445B (zh) | 2006-08-11 | 2013-04-17 | 深圳市孚沃德生物技术有限公司 | 流行性感冒原代地鼠肾细胞多价疫苗及其制备方法 |
WO2008043774A1 (en) | 2006-10-12 | 2008-04-17 | Glaxosmithkline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
-
2009
- 2009-03-18 US US12/933,379 patent/US20110014230A1/en not_active Abandoned
- 2009-03-18 CN CN2009801100894A patent/CN101998990B/zh active Active
- 2009-03-18 EP EP18203041.1A patent/EP3459563A1/en active Pending
- 2009-03-18 CA CA2718430A patent/CA2718430A1/en not_active Abandoned
- 2009-03-18 NZ NZ587798A patent/NZ587798A/xx not_active IP Right Cessation
- 2009-03-18 ES ES09721484.5T patent/ES2535101T3/es active Active
- 2009-03-18 EA EA201071086A patent/EA201071086A1/ru unknown
- 2009-03-18 AU AU2009227674A patent/AU2009227674C1/en active Active
- 2009-03-18 EP EP09721484.5A patent/EP2268309B1/en not_active Revoked
- 2009-03-18 WO PCT/IB2009/005122 patent/WO2009115917A2/en active Application Filing
- 2009-03-18 EP EP15151835.4A patent/EP2889042A3/en not_active Withdrawn
- 2009-03-18 KR KR1020107021840A patent/KR20100135766A/ko not_active Application Discontinuation
- 2009-03-18 JP JP2011500313A patent/JP5518041B2/ja active Active
-
2015
- 2015-12-07 US US14/961,778 patent/US10946088B2/en active Active
-
2021
- 2021-01-19 US US17/151,840 patent/US20210205438A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001022992A2 (en) * | 1999-09-30 | 2001-04-05 | Smithkline Beecham Biologicals S.A. | Influenza vaccine |
US20070141078A1 (en) * | 1999-09-30 | 2007-06-21 | D Hondt Erik | Influenza vaccine |
US7238349B1 (en) * | 1999-09-30 | 2007-07-03 | Smithkline Beecham Biologicals, S.A. | Composition |
WO2006100110A1 (en) * | 2005-03-23 | 2006-09-28 | Glaxosmithkline Biologicals S.A. | Novel composition |
WO2007052057A2 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Adminstration routes for priming/boosting with influenza vaccines |
US20080014217A1 (en) * | 2006-07-17 | 2008-01-17 | Emmanuel Jules Hanon | Influenza vaccine |
US20090285854A1 (en) * | 2006-07-20 | 2009-11-19 | Novartis Ag | Frozen stockpiling of influenza vaccines |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110200635A1 (en) * | 2008-06-12 | 2011-08-18 | Novartis Ag | Combined influenza vaccines for seasonal and pandemic protection |
US9821051B1 (en) * | 2010-10-28 | 2017-11-21 | Seqirus UK Limited | Reducing hospitalization in elderly influenza vaccine recipients |
US11896660B1 (en) | 2010-10-28 | 2024-02-13 | Seqirus UK Limited | Reducing hospitalization in elderly influenza vaccine recipients |
US10144917B2 (en) | 2014-08-29 | 2018-12-04 | Calixar | Method for preparing a vaccine antigen, resulting vaccine antigen and uses |
RU2741003C1 (ru) * | 2020-03-27 | 2021-01-22 | Евгений Дмитриевич Некрасов | Способ производства четырехвалентной субъединичной вакцины против гриппа без адъювантов |
Also Published As
Publication number | Publication date |
---|---|
AU2009227674C1 (en) | 2015-01-29 |
WO2009115917A2 (en) | 2009-09-24 |
CN101998990B (zh) | 2013-11-27 |
EP2889042A2 (en) | 2015-07-01 |
EP2889042A3 (en) | 2015-10-14 |
NZ587798A (en) | 2013-06-28 |
EP2268309B1 (en) | 2015-01-21 |
US20160158341A1 (en) | 2016-06-09 |
ES2535101T3 (es) | 2015-05-05 |
JP2011515387A (ja) | 2011-05-19 |
CN101998990A (zh) | 2011-03-30 |
JP5518041B2 (ja) | 2014-06-11 |
KR20100135766A (ko) | 2010-12-27 |
US10946088B2 (en) | 2021-03-16 |
AU2009227674A1 (en) | 2009-09-24 |
CA2718430A1 (en) | 2009-09-24 |
WO2009115917A3 (en) | 2010-02-04 |
EA201071086A1 (ru) | 2011-04-29 |
EP2268309A2 (en) | 2011-01-05 |
AU2009227674B2 (en) | 2014-10-16 |
EP3459563A1 (en) | 2019-03-27 |
US20210205438A1 (en) | 2021-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240050553A1 (en) | Making influenza virus vaccines without using eggs | |
US20210205438A1 (en) | Preparation of influenza virus vaccine antigens | |
US20190314483A1 (en) | Vaccines Including Antigen From Four Strains of Influenza Virus | |
US9566326B2 (en) | Adjuvanted influenza vaccines for pediatric use | |
US9901630B2 (en) | Adjuvant-sparing multi-dose influenza vaccination regimen | |
EP2185191B1 (en) | Low-additive influenza vaccines | |
CA2628152C (en) | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture | |
US20090285854A1 (en) | Frozen stockpiling of influenza vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAUSSMANN, CHRISTOPH;HAUSCHILD, FRANK;JOBST, BJORN;REEL/FRAME:025020/0744 Effective date: 20100903 |
|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS GMBH;REEL/FRAME:025346/0690 Effective date: 20101110 |
|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE TYPO IN THE PRIORITY FROM 61069898 TO 61069868 PREVIOUSLY RECORDED ON REEL 025346 FRAME 0690. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF NOVARTIS VACCINES AND DIAGNOSTICS GMBH TO NOVARTIS AG;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS GMBH;REEL/FRAME:025904/0374 Effective date: 20101110 Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS SRL;REEL/FRAME:025905/0657 Effective date: 20110223 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |